Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

Completed

Conditions studied: Acne Vulgaris

In brief

The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are administered sarecycline (Seysara®) in real-world community practice settings in the United States (U.S). Investigator's Global Assessment (IGA) of AV and safety measures associated with use of sarecycline (Seysara®) will be assessed over the study observation period of 12 weeks. Clinicians will prescribe sarecycline (Seyara®) as per their own clinical judgment and standard practice.

Key facts

Study ID
NCT04820673
Run by
Almirall, S.A.
People needed
300
Starts
2021-03-09
Expected to finish
2022-05-04
Last updated by the study team
2024-10-10

Who can join

Age: 9 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.